mRNA Vaccines
- Name
- mRNA Vaccines
- Accession Number
- DBCAT005631
- Description
Vaccines formulated with recombinant mRNAs which are taken up by the host cells that translate the mRNA and present the translated proteins to the immune system as antigens in a manner similar to that which would occur during natural infection. This induces humoral and cellular immune responses against the encoded antigen.
- Drugs
Drug Drug Description Moderna COVID-19 Vaccine An mRNA vaccine for the prevention of COVID-19 caused by the SARS-CoV-2 virus. BNT162b1 SARS-CoV-2 Vaccine BNT162b1 is one of four advanced mRNA-based vaccines being developed through "Project Lightspeed," a joint program between Pfizer and BioNTech.[L15002, L15007] BNT162b1 is a nucleoside modified mRNA (modRNA) vaccine encoding... Tozinameran An mRNA vaccine for the prevention of COVID-19 caused by the SARS-CoV-2 virus. Pidacmeran Pidacmeran is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults). BNT-162A1 BNT-162A1 is under investigation in clinical trial NCT04380701 (A Trial Investigating the Safety and Effects of Four BNT162 Vaccines Against COVID-2019 in Healthy Adults). Famtozinameran A component of a bivalent COVID-19 mRNA vaccine encoding the viral spike protein of Omicron variant lineages BA.4 and BA.5. Imelasomeran A component of a bivalent COVID-19 mRNA vaccine encoding the viral spike protein of Omicron variant lineage BA.1. Riltozinameran A component of a bivalent COVID-19 mRNA vaccine encoding the viral spike protein of Omicron variant lineage BA.1. Andusomeran An mRNA vaccine for the prevention of COVID-19 caused by the SARS-CoV-2 virus, including the XBB.1.5 subvariant. - Drugs & Drug Targets
Drug Target Type